8-K
filed January 12, 2026, 6:59 PM ET
ticker MGX
CIK 0001785279
other material
confidence high
sentiment positive
materiality 0.60
Metagenomi renames to Metagenomi Therapeutics; hemophilia A program on track for IND in 2026
Metagenomi Therapeutics, Inc.
- Name changed to Metagenomi Therapeutics, Inc. effective Jan 12, 2026; ticker MGX unchanged.
- Lead program MGX-001: pre-IND meeting completed; IND/CTA on track for Q4 2026.
- Preclinical data showed curative FVIII activity in NHPs with no off-target editing.
- Cash runway extended to Q4 2027 following strategic pipeline prioritization.
- Jian Irish appointed CEO as part of strategic evolution toward in vivo gene editing.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Metagenomi Therapeutics, Inc.: Amended certificate of incorporation to change company name from Metagenomi, Inc. to Metagenomi Therapeutics, Inc (effective 2026-01-12).
- Change
- charter amendment
- Effective
- 2026-01-12
Exact text from the filing
filed a certificate of amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), solely to change the Company’s name from “Metagenomi, Inc.” to “Metagenomi Therapeutics, Inc.” (the “Name Change”), which became effective at 12:01 a.m. Pacific Time on January 12, 2026.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Metagenomi Therapeutics, Inc.: Amended and restated bylaws solely to reflect the name change (effective 2026-01-12).
- Change
- bylaw amendment
- Effective
- 2026-01-12
Exact text from the filing
the Company’s Board also amended and restated its Amended and Restated Bylaws (as amended, the “Second Amended and Restated Bylaws”), effective on January 12, 2026, solely to reflect the Name Change.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.